{"analyses":[{"ciLowerLimit":"0.57","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.29","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Cox Proportional Hazard","paramValue":"0.85","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"comment":"Not estimable due to 69 out of 113 patients were still alive at data cutoff date","groupId":"OG000","lowerLimit":"53.6","upperLimit":"NA","value":"62.6"},{"comment":"Not estimable due to 61 out of 108 patients were still alive at data cutoff date","groupId":"OG001","lowerLimit":"41.6","upperLimit":"NA","value":"59.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"108"}],"units":"Participants"}],"description":"Overall survival was defined as the time between randomization and death. Participants who die, regardless of the cause of the death, were considered to have had an event. All participants who were lost to follow-up prior to the end of the trial or who were withdrawn from the trial were censored at the time of last contact. Participants who were still being treated were censored at the last available date the subject was known to be alive, or clinical cut-off date if it was earlier.\n\nData collection is ongoing and future data results will be included as available.","dispersionType":"95% Confidence Interval","groups":[{"description":"Combination therapy of 4 mg pomalidomide given once per day on Days 1-21 of each 28-day cycle and the starting dose of dexamethasone (either 40mg or 20 mg) on days 1, 8, 15, and 22 of each 28-day cycle.","id":"OG000","title":"Phase 2: Pomalidomide + Dexamethasone"},{"description":"4 mg pomalidomide was given once per day on Days 1-21 of each 28-day cycle until PD. Participants in the single agent pomalidomide treatment arm who developed confirmed PD at any time had the option to receive oral dexamethasone at the starting dose in addition to their current dose of pomalidomide or to discontinue treatment.","id":"OG001","title":"Phase 2: Pomalidomide"}],"paramType":"MEDIAN","populationDescription":"ITT population.\n\nData collection is ongoing and future data results will be included as available.","reportingStatus":"POSTED","timeFrame":"up to 70 weeks","title":"Phase 2: Kaplan-Meier Estimates of Overall Survival as of the 01 April 2011 Cut-off","type":"SECONDARY","unitOfMeasure":"weeks"}